Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

We'll tackle several other positions this offseason and we'll refer back to these pieces once we begin the next batch of Film Study content! During the season, we do a lot of "Film Study" content in ...